布地格福联合泛福舒改善稳定期COPD患者肺功能的临床研究  

Clinical study of budesonide combined with pentopril in improving pulmonary function in patients with stable chronic obstructive pulmonary disease

作　　者：王杨广 麦景亮 张建平 WANG Yang-guang;MAI Jing-liang;ZHANG Jian-ping(Department of Respiratory and Critical Care Medicine,Taishan Second People's Hospital,Taishan 529224,Guangdong,CHINA)

机构地区：[1]台山市第二人民医院呼吸与危重症医学科,广东台山529224

出　　处：《海南医学》2023年第21期3074-3077,共4页Hainan Medical Journal

摘　　要：目的研究布地格福联合泛福舒改善稳定期慢性阻塞性肺疾病(COPD)患者肺功能的临床效果。方法选取2021年6月至2022年10月期间台山市第二人民医院收治的80例稳定期COPD患者作为研究对象,按随机数表法将患者分为联合组和对照组各40例。对照组患者采用布地格福治疗,联合组患者采用布地格福联合泛福舒治疗,两组患者均连续治疗3个月。比较两组患者的治疗效果,治疗前及治疗1个月、2个月、3个月后的肺功能指标[第一秒用力呼气容积(FEV_(1))、用力肺活量(FVC)、FEV_(1)/FVC],治疗前后的免疫球蛋白指标[免疫球蛋白A(IgA)、免疫球蛋白G(IgG)、免疫球蛋白M(IgM)]和治疗期间的不良反应发生情况。结果联合组患者的治疗总有效率为95.00%,明显高于对照组患者的75.00%,差异有统计学意义(P<0.05);治疗前,两组患者的FEV_(1)、FVC、FEV_(1)/FVC比较差异均无统计学意义(P>0.05),治疗1个月、2个月、3个月后,两组患者的FEV_(1)、FVC、FEV_(1)/FVC均明显升高,且联合组明显高于对照组,差异均具有统计学意义(P<0.05);治疗前,两组患者的IgA、IgG、IgM比较差异均无统计学意义(P>0.05),治疗后,两组患者的IgA、IgG、IgM均升高,且联合组患者的IgA、IgG、IgM水平分别为(2.32±0.42)g/L、(13.06±2.48)g/L、(1.96±0.21)g/L,明显高于对照组的(1.76±0.38)g/L、(9.82±2.56)g/L、(1.68±0.34)g/L,差异均有统计学意义(P<0.05);联合组患者的不良反应总发生率为22.50%,略低于对照组的30.00%,但差异无统计学意义(P>0.05)。结论布地格福联合泛福舒治疗稳定期COPD患者效果好,不仅能显著改善稳定期COPD患者的肺功能,而且能有效改善患者的免疫功能,安全性较高,具有临床应用价值。Objective To study the clinical effect of budesonide combined with pantopril on improving pulmonary function in patients with stable chronic obstructive pulmonary disease(COPD).Methods Eighty stable COPD patients admitted to Taishan Second People's Hospital from June 2021 to October 2022 were selected and randomly divided into a combined group and a control group,each with 40 cases.Patients in the control group were treated with budesonide,while those in the combined group were treated with budesonide combined with pentopril,both continuously for 3 months.The treatment effects were compared between the two groups,as well as lung function indicators[first second forced expiratory volume(FEV_(1)),forced vital capacity(FVC),and FEV_(1)/FVC)]before and after 1,2,and 3 months of treatment,immunoglobulin indicators[immunoglobulin A(IgA),immunoglobulin G(IgG),immunoglobulin M(IgM)]before and after treatment,and the occurrence of adverse reactions during treatment.Results The total effective rate of the combined group was 95.00%,which was significantly higher than 75.00%of the control group(P<0.05).Before treatment,there was no statistically significant difference in FEV_(1),FVC,and FEV_(1)/FVC between the two groups(P>0.05);after 1,2,and 3 months of treatment,the FEV_(1),FVC,and FEV_(1)/FVC of the two groups were significantly increased,and the levels in the combined group were significantly higher than those in the control group;the differences were all statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the levels of IgA,IgG,and IgM between the two groups(P>0.05);after treatment,the levels of IgA,IgG,and IgM in both groups increased,and the levels of IgA,IgG,and IgM in the combined group were(2.32±0.42)g/L,(13.06±2.48)g/L,and(1.96±0.21)g/L,which were significantly higher than(1.76±0.38)g/L,(9.82±2.56)g/L,and(1.68±0.34)g/L in the control group;the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the combined group wa

关 键 词：慢性阻塞性肺疾病 布地格福 泛福舒 肺功能 免疫球蛋白 疗效 

分 类 号：R563[医药卫生—呼吸系统]